GlassScriptPhysician profile
Zulekha I Karim
NPI 1861812844
$4,870.36
in general payments reported to CMS, 2019-2025
43 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $329 · 2021: $1,433 · 2022: $557 · 2023: $445 · 2024: $441 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $690.66 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $440.00 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $364.39 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $330.67 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $293.93 | 2020-2025 | |
| Dexcom, INC. | $287.36 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $281.03 | 2020-2025 | |
| Pfizer INC. | $245.18 | 2020-2024 | |
| Amgen INC. | $210.21 | 2021-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $151.93 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $139.14 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $131.98 | 2021-2025 | Isturisa |
| Insulet Corporation | $112.41 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $105.51 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.90 | 2020-2025 | Jardiance, Tradjenta |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zulekha Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.